Adjuvant Radiotherapy for Surgically Resected Stage III Merkel Cell Carcinoma
Cette étude analyse l'intérêt d'une radiothérapie adjuvante chez des patients atteints d'un carcinome à cellules de Merkel de stade III ayant subi une chirurgie
Adjuvant radiotherapy (aRT) to the primary tumor site is associated with reduced recurrence and improved survival in stage I to II Merkel cell carcinoma (MCC). Its utility in stage III MCC remains a controversial topic. One study demonstrated improved overall survival (OS) in patients with stage III disease who underwent complete lymph node (LN) dissection and received aRT. Another did not demonstrate benefit of aRT with nodal disease. This case-control study evaluated whether aRT is associated with OS in surgically resected stage III MCC.
JAMA Surgery 2024